Changes in diffusion-weighted images for visualizing prostate cancer during antiandrogen therapy: Preliminary results

Urologia Internationalis

Volumn 85, Issue 4, 2010, Pages 421-426

  Nemoto, Kaoru ^a   Tateishi, Toshiki ^b   Ishidate, Takuzo ^c  

^a NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

^c Hakodate Hospital   (Japan)

Author keywords

Antiandrogen therapy; Diffusion weighted imaging; Prostate specific antigen kinetics; Transrectal ultrasound

Indexed keywords

BICALUTAMIDE; CHLORMADINONE ACETATE; GOSERELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANTIANDROGEN THERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER PATIENT; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; DIFFUSION MAGNETIC RESONANCE IMAGING; DIGITAL RECTAL EXAMINATION; HUMANS; JAPAN; MALE; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; ULTRASONOGRAPHY, DOPPLER;

EID: 78650995183     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321233     Document Type: Article

References (15)

1. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE: Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 2002; 168: 995-1000.
2. Fitzpatrick JM, Banu E, Oudard S: Prostatespecific antigen kinetics in localized and advanced prostate cancer. BJU Int 2009; 103: 578-587.
3. Komiya A, Suzuki H, Imamoto T, Kamiya N, Nihei N, Naya Y, Ichikawa T, Fuse H: Neuroendocrine differentiation in the progression of prostate cancer. Int J Urol 2009; 16: 37-44.
4. Koh DM, Colins DJ: Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR AM J Roentgenol 2007; 188: 1622-1635.
5. Seitz M, Shukla-Dave A, Bjartell A, Touijer K, Sciarra A, Bastian PJ, Stief C, Hricak H, Graser A: Functional magnetic resonance imaging in prostate cancer. Eur Urol 2009; 55: 801-814.
6. Pinault S, Têtu B, Gagnon J, Monfette G, Dupont A, Labrie F: Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination with flutamide. Urology 1992; 39: 254-261.
7. Chen M, Hricak H, Kalbhen CL, Kurhanewicz J, Vigneron DB, Weiss JM, Carroll PR: Hormonal ablation of prostatic cancer: Effects on prostate morphology, tumor detection, and staging by endorectal coil MR imaging. AJR Am J Roentgenol 1996; 166: 1157-1163.
8. Padhani AR, MacVicar AD, Gapinski CJ, Dearnaley DP, Parker GJ, Suckling J, Leach MO, Husband JE: Effects of androgen deprivation on prostatic morphology and vascular permeability evaluated with MR imaging. Radiology 2001; 218: 365-374.
9. Okihara K, Watanabe H, Kojima M: Kinetic study of tumor blood flow in prostatic cancer using power Doppler imaging. Ultrasound Med Biol 1999; 25: 89-94.
10. Eckersley RJ, Sedelaar JP, Blomley MJ, Wijkstra H, deSouza NM, Cosgrove DO, de la Rosette JJ: Quantitative microbubble enhanced transrectal ultrasound as a tool for monitoring hormonal treatment of prostate carcinoma. Prostate 2002; 51: 256-267.
11. Kitajima K, Kaji Y, Kuroda K, Sugimura K: High b-value diffusion-weighted imaging in normal and malignant peripheral zone tissue of the prostate: effect of signal-to-noise ratio. Magn Reson Med Sci 2008; 7: 93-99.
12. Kim CK, Park BK, Kim B: High-b-value diffusion- weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm 2 . AJR Am J Roentgenol 2010; 194:w33-w37.
13. Vilanova JC, Barcelo J: Diffusion-weighted whole-body MR screening. Eur J Radiol 2008; 67: 440-447.
14. Venkitaraman R, Cook GJ, Dearnaley DP, Parker CC, Khoo V, Eeles R, Huddart RA, Horwich A, Sohaib SA: Whole-body magnetic resonance imaging in the detection of skeletal metastases in patients with prostate cancer. J Med Imaging Radiat Oncol 2009; 53: 241-247.
15. Kim CK, BK Park, HM Lee: Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion- weighted MRI. J Magn Reson Imaging 2009; 29: 391-397.